Articles

Low potassium is usually viewed through a cardiovascular lens, especially in patients with heart failure. However, emerging evidence suggests clinicians may have another reason to pay attention. New research examining the relationship between hypokalemia and diabetes risk found that lower serum potassium levels were associated with a greater risk of …

When glucose numbers improve, patients are expected to feel better. Yet some people with type 1 diabetes report the opposite. A glucose level that looks reassuring on a continuous glucose monitor may leave them feeling tired, uncomfortable, or simply “off.” New research suggests that glycemic habituation may help explain this …

SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2 diabetes, heart failure, and chronic kidney disease. That success raises an obvious question: why are SGLT inhibitors in type 1 diabetes still largely outside routine clinical practice? The answer is not a …

For people with painful diabetic neuropathy (PDN), treatment has traditionally focused on controlling burning, stabbing, and shooting pain. However, emerging research on spinal cord stimulation for diabetic neuropathy raises a more intriguing question: Could neuromodulation also improve sensation? Results from the SENZA-PDN clinical trial suggest that some patients receiving high-frequency …

Could a routine blood sample someday reveal cardiovascular danger that cholesterol, blood pressure, and HbA1c do not fully capture? New research suggests that epigenetic cardiovascular risk prediction could offer a new way to identify people with type 2 diabetes who face a higher short-term risk of major cardiovascular events. Instead …

GLP-1 receptor agonists have transformed the treatment of type 2 diabetes, but their effects on gastrointestinal motility remain an important clinical consideration. Opioids can also slow gastrointestinal function, raising an obvious question: what happens when patients need both? New research examining GLP-1 and opioid interactions suggests that opioid choice may …

Managing glucose is rarely simple for people with Type 2 diabetes who receive maintenance hemodialysis. Dialysis can change glucose patterns, insulin needs, and the reliability of familiar measures such as A1C. As a result, clinicians may have an incomplete picture when making treatment decisions. New randomized research on CGM use …

Three decades of advances in diabetes care have transformed how people with type 1 diabetes manage glucose. Insulin pumps, continuous glucose monitoring (CGM), improved insulin analogs, automated insulin delivery, and earlier screening have all changed daily treatment. However, have these advances actually reduced the long-term complications of type 1 diabetes? …

Gestational diabetes is usually treated as a single diagnosis, but growing evidence suggests the biology behind it can vary considerably from one patient to another. Researchers studying gestational diabetes phenotypes have identified metabolic patterns involving differences in insulin resistance, insulin secretion, or both. These findings raise an important question: Could …

A1C is one of the most useful tools in diabetes care, but it has an important limitation: it takes time to reflect change. Could a faster-moving marker help clinicians know sooner whether treatment is working? New randomized research on glycated albumin in diabetes offers an intriguing answer. Glycated albumin reflects …